Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003793-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the independently assessed progression free survival of subjects with clear cell type renal cell carcinoma (all risk groups) treated with bevacizumab + temsirolimus (experimental) versus bevacizumab + interferon-alfa (control) in subjects with advanced renal cell carcinoma.


Critère d'inclusion

  • First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma